News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer …a wide range of cancers.” Better efficacy and safety Spirea’s technology allows more cytotoxic drug to be attached to the targeting antibody (a higher drug-to-antibody ratio), which means more drug… June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients …candidate, ADCT-402, in tough-to-treat lymphomas and leukemias were presented at the annual American Society of Hematology (ASH) Meeting. The candidate has shown potential in the treatment of Diffuse Large B-Cell… December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Podcast 31 Mar 2023 Beyond Biotech podcast 40: Antibody-drug conjugates This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology… March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Apr 2019 The 8 Best Biotech Companies in Europe’s History …human antibody and the world’s best selling drug during the last few years. After selling and licensing several human antibodies to big pharma, Cambridge Antibody Technology was acquired in 2006… April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Podcast 7 Jul 2023 Beyond Biotech podcast 53: Antibody-drug conjugates On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink… July 7, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2019 Innate Pharma Raises €62M IPO to Develop Antibody Drugs for Cancer The French company Innate Pharma has raised a Nasdaq IPO of €62.1M ($68.8M) to fund the development of antibody immunotherapies for solid tumors and blood cancer. Innate Pharma’s lead candidate… October 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Scancell looking to partner after positive COVID vaccine data …cell response. RBD neutralizing antibody titres against the Beta variant doubled in 44% of subjects and NCAP antibody titres doubled in 42% of participants. Scancell said of particular interest was… February 14, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 New Antibodies to Target the Respiratory Syncytial Virus …an RSV therapy is already quite crowded, but Arsanis seems to be confident that their new antibody candidates have the potential to compete. Images via shutterstock.com / Kateryna Kon … February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2025 XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry? …to BioInvent in exchange for upsizing our royalty.” The antibody drug was born from BioInvent’s n-CoDeR antibody library containing more than 30 billion human antibody genes stored within phage viruses… July 11, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2024 Overcoming toxicities: are IL-2 smart cytokines the next big thing? …has two IL-2 smart cytokine candidates in the running. Its phase 1 candidate BNT151 is being developed to treat multiple solid tumors including head and neck cancer, liver cancer, and… April 24, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Jan 2025 Top 19 most-performing biotech stocks of 2024 …of MNPR-101-Lu, a novel radiopharmaceutical treating aggressive solid tumors. This is the candidate Monopar decided to prioritize after Validive’s mitigated results. This compound combines MNPR-101, a humanized monoclonal antibody that… January 27, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Dec 2024 Five biosimilar companies you should know about …Biogen Ongoing partnership with Merck for biosimilar candidates Samsung Bioepis is advancing a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology,… December 5, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email